Mechanism of action of the bimodal antidepressant vilazodone: Evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output

Psychopharmacology

Volumn 231, Issue 12, 2014, Pages 2547-2558

  Van Amsterdam, Christoph ^a,b   Seyfried, Christoph A ^a,c  

^a MERCK KGAA   (Germany)

^b Merck Serono GmbH   (Germany)

^c NONE   (Germany)

Author keywords

5 Hydroxytryptophan accumulation; Antidepressants; Intrinsic activity; Microdialysis; Vilazodone

Indexed keywords

5 HYDROXYTRYPTOPHAN; AUTORECEPTOR; CITALOPRAM; DOPAMINE; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; VILAZODONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; EX VIVO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; ANIMAL; BRAIN; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; EXTRACELLULAR SPACE; METABOLISM; WISTAR RAT;

5-HYDROXYTRYPTOPHAN; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; BRAIN; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTRACELLULAR SPACE; FLUOXETINE; INDOLES; MALE; PAROXETINE; PIPERAZINES; PYRIDINES; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84902162974     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3428-7     Document Type: Article

References (34)

1. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F (2005) Strategies for producing faster acting antidepressants. Drug Discov Today 10:578-585
2. 1A receptor antagonists NAD-299, WAY-100635 and (S)-(-)-UH-301 at rat brain monoamine receptors. Eur Neuropsychopharmacol 9:15-19
3. Arborelius L, Wallsten C, Ahlenius S, Svensson TH (1999) The 5-HT1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur J Pharmacol 382:133-138
4. Ashby CR Jr, Kehne JH, Bartoszyk GD, Renda MJ, Athanasiou M, Pierz KA, Seyfried CA (2013) Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol 714:359-365
5. Bartoszyk GD, Hegenbart R, Ziegler H (1997) EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 322:147-153
6. Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153-160
7. Beyer CE, Cremers TIFH (2008) Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol 580:350-354
8. Carlsson A, Lindqvist M (1970) Accumulation of 5-hydroxytryptophan in mouse brain after decarboxylase inhibition. J Pharm Pharmacol 22:726-727
9. 1A agonists. Synapse 14:297-304
10. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 345:41-46
11. 1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 15:107-117
12. Deguchi T, Sinha AK, Barchas JD (1973) Biosynthesis of serotonin in raphé nuclei of rat brain: effect of p-chlorophenylalanine. J Neurochem 20:1329-1336
13. 1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 278:752-762
14. Fuller RW, Snoddy HD, Snoddy AM, Hemrick SK, Wong DT, Molloy BB (1980) p-iodoamphetamine as a serotonin depletor in rats. J Pharmacol Exp Ther 212:115-119
15. Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain: I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 13:655-669
16. 1A receptor agonists and serotonin reuptake inhibitors. J Med Chem 47:4684-4692
17. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510:49-57
18. 1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 283:216-225
19. Khan A (2009) Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 18:1753-1764
20. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR (2011) A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 72:441-447
21. 1A receptor antagonists. Eur J Pharmacol 346:209-215
22. 1A receptor antagonists on dorsal raphe cell firing. J Pharmacol Exp Ther 288:820-826
23. Meller E, Bohmaker K (1994) Differential receptor reserve for 5-HT1A receptor-mediated regulation of plasma neuroendocrine hormones. J Pharmacol Exp Ther 271:1246-1252
24. 1A agonists. Mol Pharmacol 37:231-237
25. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340:666-675
26. 1A receptor partial agonist. J Pharmacol Exp Ther 302:1220-1227
27. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Orlando
28. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR (2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder, a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70:326-333
29. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 219:123-126
30. Seyfried CA, Adam G, Greve T (1986) An automated direct-injection HPLC- method for the electrochemical/fluorimetric quantitation of monoamines and related compounds optimized for the screening of large numbers of animals. Biomed Chromatogr 1:78-88
31. 2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160:31-41
32. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96:283-290
33. Stenfors C, Yu H, Ross SB (2001) Pharmacological characterization of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram. Naunyn Schmiedebergs Arch Pharmacol 363:222-232
34. 1A receptors is mediated by activation of protein kinase A (PKA) in rat serotonergic neurons. Neuroscience 169:87-97